Why this exists

Two separate failures meet here. The first is the therapy gap: a patient who cannot reach a pharmacy, or whose pharmacy is out of stock, simply stops taking a medication they are physically dependent on. Withdrawal, uncontrolled pain, an emergency department visit and sometimes a turn to the illicit supply follow from that. DEA’s own 2025 production quota order records public comments describing exactly this — pharmacies out of stock, patients calling around and traveling further, and many unsuccessful.

The second is quieter. When a patient cannot collect medication themselves, somebody else does. A family member, a neighbor, a paid driver. That handoff is an unsupervised link in the chain, and it is a link that nobody records. Removing it is a diversion control that does not require accusing anyone of anything.

How it works

• Partnership, not ownership. IntellaRx is not a pharmacy and does not dispense. The program works with licensed pharmacy partners who do.
• Scheduled ahead of run-out. Delivery is timed against the prescription so the patient receives the next supply before the current one ends, and adjusted when the prescription changes.
• Signed for by the patient or an authorized adult. Every delivery, with identification confirmed at the point of transfer — see biometric cross-validation.
• Drivers trained on confidentiality and on what they are carrying. This is not a parcel service that happens to carry controlled substances.
• Coordinated with the prescriber. A cancellation or dose change has to reach the delivery schedule the same day, or the program has created a new failure mode instead of fixing an old one.

Where a patient has no stable address, delivery is the wrong instrument and the program says so — see social determinants verification for how that is identified before someone is enrolled in something that cannot work for them.